Figure 5

NAD⁺ promotes skin allograft survival through a systemic increase of IL-10.

Fully MHC-mismatched C57BL/B6 tail skin allografts were transplanted onto DBA/2 mice that received daily doses of NAD⁺ (40 mg in 100 μl PBS) or control solution (PBS). (a) Skin graft survival was monitored (n = 6 per group) and (b) CD4⁺ T cells were isolated from spleens of wild type mice 8 days after transplantation and frequencies of IL-10⁺, IL-17A⁺ and IFNγ⁺ cells were analyzed by flow cytometry (n = 6 per group, representative plots shown). (c) Fully MHC-mismatched DBA tail skin allografts were transplanted onto IL-10^−/−(C57BL/6 background), CD4^−/− (C57BL/6 background), (and wild type (WT) mice that received daily doses of NAD⁺ (40 mg in 100 μl PBS) or control solution (PBS) and skin graft survival was monitored (n = 6 per group). Data derived from two independent experiments. Data represent mean ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001. Student’s t-test, ANOVA tests and Log-rank test were used to compare groups accordingly.